$15.16
1.10%
NYSE, Sep 02, 07:49 pm CET
ISIN
US8740602052
Symbol
TAK

Takeda Pharmaceutical Co. Ltd. Sponsored ADR Stock price

$14.99
+0.67 4.68% 1M
+0.58 4.03% 6M
+1.75 13.22% YTD
+0.04 0.27% 1Y
+1.22 8.86% 3Y
-3.62 19.45% 5Y
-9.55 38.90% 10Y
-12.36 45.19% 20Y
NYSE, Closing price Fri, Aug 29 2025
+0.02 0.13%
ISIN
US8740602052
Symbol
TAK
Industry

Key metrics

Basic
Market capitalization
$47.6b
Enterprise Value
$75.4b
Net debt
$27.8b
Cash
$2.8b
Shares outstanding
1.6b
Valuation (TTM | estimate)
P/E
25.4 | 14.4
P/S
1.6 | 1.5
EV/Sales
2.5 | 2.4
EV/FCF
13.6
P/B
1.0
Dividends
DPS
$0.67
Yield 1Y | 5Y
4.4% | 4.5%
Growth 1Y | 5Y
8.8% | -4.3%
Payout 1Y | 3Y
144.6% | 77.9%
Increased
1 Year
Financials (TTM | estimate)
Revenue
$30.4b | $31.3b
EBITDA
$6.6b | $8.3b
EBIT
$2.8b | $2.7b
Net Income
$930.3m | $1.6b
Free Cash Flow
$5.6b
Growth (TTM | estimate)
Revenue
1.5% | 0.4%
EBITDA
2.3% | 11.0%
EBIT
1.0% | -25.2%
Net Income
-8.7% | 122.3%
Free Cash Flow
84.1%
Margin (TTM | estimate)
Gross
64.8%
EBITDA
21.7% | 26.6%
EBIT
9.3%
Net
3.1% | 5.2%
Free Cash Flow
18.3%
Financial Health
Equity Ratio
48.7%
Return on Equity
1.6%
ROCE
3.5%
ROIC
2.6%
Debt/Equity
0.7
More
EPS
$0.6
FCF per Share
$3.6
Short interest
0.3%
Employees
49k
Rev per Employee
$630.0k
Show more

Is Takeda Pharmaceutical Co. Ltd. Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Takeda Pharmaceutical Co. Ltd. Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

20 Analysts have issued a Takeda Pharmaceutical Co. Ltd. Sponsored ADR forecast:

11x Buy
55%
9x Hold
45%

Analyst Opinions

20 Analysts have issued a Takeda Pharmaceutical Co. Ltd. Sponsored ADR forecast:

Buy
55%
Hold
45%

Financial data from Takeda Pharmaceutical Co. Ltd. Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
30,439 30,439
2% 2%
100%
- Direct Costs 10,721 10,721
6% 6%
35%
19,718 19,718
1% 1%
65%
- Selling and Administrative Expenses 7,410 7,410
1% 1%
24%
- Research and Development Expense 4,794 4,794
4% 4%
16%
6,610 6,610
2% 2%
22%
- Depreciation and Amortization 3,765 3,765
3% 3%
12%
EBIT (Operating Income) EBIT 2,844 2,844
1% 1%
9%
Net Profit 930 930
9% 9%
3%

In millions USD.

Don't miss a Thing! We will send you all news about Takeda Pharmaceutical Co. Ltd. Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Takeda Pharmaceutical Co. Ltd. Sponsored ADR Stock News

Positive
Reuters
13 days ago
Japanese drugmaker Takeda Pharmaceutical is exploring the option of conducting global clinical trials in India to accelerate the launch of its innovative drugs in the world's most populous nation, its India head told Reuters.
Neutral
Seeking Alpha
about one month ago
Takeda Pharmaceutical Company Limited (NYSE:TAK ) Q1 FY2025 Earnings Call July 30, 2025 6:00 AM ET Company Participants Furuta - Corporate Participant O'Reilly - Corporate Participant Plump - Corporate Participant Weber - Corporate Participant Conference Call Participants Barker - Unidentified Company Kim - Unidentified Company Matsubara - Unidentified Company Muraoka - Unidentified Company Ned...
Neutral
Business Wire
about one month ago
OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the first quarter of fiscal year 2025 (three months ended June 30, 2025), with generic erosion of VYVANSE significantly impacting revenue and Core Operating Profit in line with company expectations for the quarter. The company expects these impacts to moderate in future quarters. Takeda also achieve...
More Takeda Pharmaceutical Co. Ltd. Sponsored ADR News

Company Profile

Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.

Head office Japan
CEO Christophe Weber
Employees 49,281
Founded 1781
Website www.takeda.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today